About GeoVax Labs, Inc.
https://www.geovax.comGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform.
CEO
David Alan Dodd
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-31 | Reverse | 1:15 |
| 2020-09-25 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
SABBY MANAGEMENT, LLC
Shares:661.38K
Value:$1.89M
ARMISTICE CAPITAL, LLC
Shares:533.9K
Value:$1.53M
VANGUARD GROUP INC
Shares:244.16K
Value:$698.31K
Summary
Showing Top 3 of 24
About GeoVax Labs, Inc.
https://www.geovax.comGeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $6.36M ▲ | $-6.32M ▼ | 0% ▲ | $-0.31 ▲ | $-6.3M ▼ |
| Q2-2025 | $852.28K ▼ | $6.27M ▼ | $-5.37M ▼ | -630.05% ▼ | $-0.35 ▲ | $-5.35M ▼ |
| Q1-2025 | $1.64M ▲ | $7.03M ▼ | $-5.36M ▲ | -327.31% ▲ | $-0.45 ▲ | $-5.34M ▲ |
| Q4-2024 | $864.41K ▼ | $9.19M ▲ | $-8.26M ▼ | -955.87% ▼ | $-0.78 ▲ | $-8.24M ▼ |
| Q3-2024 | $2.79M | $8.64M | $-5.82M | -208.48% | $-0.91 | $-5.77M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $5.01M ▲ | $6.73M ▲ | $1.82M ▼ | $4.91M ▲ |
| Q2-2025 | $3.09M ▼ | $5.35M ▼ | $2.53M ▼ | $2.82M ▼ |
| Q1-2025 | $7.44M ▲ | $10.83M ▲ | $2.94M ▼ | $7.9M ▲ |
| Q4-2024 | $5.51M ▼ | $8.16M ▼ | $3.11M ▲ | $5.05M ▼ |
| Q3-2024 | $8.59M | $11.11M | $2.61M | $8.5M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-6.32M ▼ | $-6.21M ▼ | $0 ▲ | $8.13M ▲ | $1.92M ▲ | $-6.21M ▼ |
| Q2-2025 | $-5.37M ▼ | $-4.33M ▲ | $-10.72K ▲ | $209 ▼ | $-4.34M ▼ | $-4.33M ▲ |
| Q1-2025 | $-5.36M ▲ | $-5.97M ▲ | $-16.89K ▼ | $7.91M ▲ | $1.93M ▲ | $-5.97M ▲ |
| Q4-2024 | $-8.26M ▼ | $-7.75M ▲ | $0 ▲ | $4.67M ▼ | $-3.09M ▼ | $-7.75M ▲ |
| Q3-2024 | $-5.82M | $-9.3M | $-20.65K | $16.35M | $7.03M | $-9.32M |
Revenue by Products
| Product | Q1-2022 |
|---|---|
 NIAID Grant | $0 ▲ |
CEO
David Alan Dodd
Compensation Summary
(Year 2022)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-01-31 | Reverse | 1:15 |
| 2020-09-25 | Reverse | 1:20 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
SABBY MANAGEMENT, LLC
Shares:661.38K
Value:$1.89M
ARMISTICE CAPITAL, LLC
Shares:533.9K
Value:$1.53M
VANGUARD GROUP INC
Shares:244.16K
Value:$698.31K
Summary
Showing Top 3 of 24